CYT006-AngQb
CYT006-AngQb is an experimental vaccine specifically formulated to target angiotensin II, with the primary objective of reducing blood pressure. While the vaccine showed some promise in clinical trials, its efficacy was found to be inferior when compared to conventional antihypertensive drugs.
Overview[edit | edit source]
CYT006-AngQb operates by eliciting an immune response against angiotensin II, a peptide hormone that plays a pivotal role in regulating blood pressure. By neutralizing or reducing the levels of this hormone, the vaccine aims to facilitate a reduction in blood pressure.
Clinical Trials[edit | edit source]
During the clinical trials, CYT006-AngQb demonstrated a certain degree of efficacy in lowering blood pressure. However, when its performance was juxtaposed against traditional antihypertensive medications, the vaccine's ability to manage hypertension was comparatively lesser.
Results and Observations[edit | edit source]
- Patients exhibited a moderate reduction in morning blood pressure.
- The side effects were minimal and comparable to placebo.
- The duration of the vaccine's efficacy needs further exploration, as does its long-term safety profile.
Potential Benefits and Limitations[edit | edit source]
Benefits[edit | edit source]
- Convenience: Being a vaccine, CYT006-AngQb offers a more extended duration of action compared to daily drug regimens.
- Safety: Preliminary trials indicate a favorable safety profile.
Limitations[edit | edit source]
- Efficacy: CYT006-AngQb was less effective than most conventional hypertension drugs in clinical settings.
- Unknown Long-Term Effects: The vaccine's long-term effects on the immune system and overall health are not yet fully understood.
Future Prospects[edit | edit source]
Further studies are needed to ascertain the full potential of CYT006-AngQb. Researchers are looking into possible combination therapies where the vaccine might be used alongside other antihypertensive agents to maximize its therapeutic benefits.
See Also[edit | edit source]
| CYT006-AngQb Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
